<DOC>
	<DOCNO>NCT00360867</DOCNO>
	<brief_summary>This extension study provide ongoing treatment AMG 706 monotherapy subject solid tumor complete planned duration AMG 706 treatment separate Amgen protocol evaluate stable disease well . Subjects longer eligible continue AMG 706 treatment separate Amgen protocol ( reason AMG 706 intolerance ) , receive clinical benefit potential receive clinical benefit AMG 706 per investigator also eligible participate trial .</brief_summary>
	<brief_title>An Open Label Treatment Extension Study AMG 706</brief_title>
	<detailed_description />
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Women men 18 yr old solid tumor , previously treat AMG 706 Amgen protocol Subject must meet one follow criterion : Subject complete planned duration AMG 706 treatment separate Amgen protocol evaluate stable disease well longer eligible continue AMG 706 treatment separate Amgen protocol reason AMG 706 intolerance , receive clinical benefit AMG 706 judgement investigator . Subject must meet one follow criterion : Subject receive AMG 706 least 8 week first protocolspecified tumor evaluation ( whichever longer ) Subject receive least one dose AMG 706 receive AMG 706 =/ &gt; 8 week . Sign inform consent prior study specific procedure . Discontinued prior AMG 706 study due AMG 706related adverse event include intolerance AMG 706 reason subject 's safety could compromise continue AMG 706 treatment . Has AMG 706 treatment &gt; 42 day prior study day 1 . Participating intervene investigational device drug study previous AMG 706 study AMG 706 study receive investigational agent ( ) AMG 706 . Uncontrolled hypertension ( rest blood pressure &gt; 150/90 mmHg ) . Antihypertensive medication allow subject stable current dose time study day1 Requires additional systemic anticancer therapy primary tumor . ANC &lt; 1.0 x 10^9/L ; PLT &lt; 100 x 10^9/L ; Hgb &lt; 9 g/dL ; serum creatinine &gt; 2.0 mg/dL calculate clearance &lt; 40 mL/min ; AST &gt; 2.5 x ULN , AST =/ &gt; =/ &gt; 5.0 x ULN secondary liver metastasis ; ALT &gt; 2.5 x ULN ALT =/ &gt; 5X ULN liver metastasis present ; Alkaline phosphates &gt; 2.0 x ULN =/ &gt; 5 x ULN liver bone metastasis present ; total bilirubin =/ &gt; 2 x ULN ( except subject UGT1A1 promoter polymorphism , ie , Gilbert 's syndrome . Subjects enrol Gilbert 's syndrome must total bilirubin &lt; 3 x ULN ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Extension study</keyword>
	<keyword>solid tumor</keyword>
</DOC>